Myelodysplastic syndromes (MDS) comprise a heterogeneous group of acquired clonal hematopoietic stem-cell disorders, characterized by ineffective hematopoiesis and a variable risk of transformation to acute myeloid leukemia. The etiology of MDS is unknown in the majority of cases; however, models for development of sporadic MDS suggest the role of cumulative genetic and toxic environmental factors in genetically predisposed individuals. 1 Human glutathione-S-transferases (GSTs) are a multigene family of phase-II cytosolic enzymes that mediate conjugation of electrophilic compounds to glutathione. They play an important role in detoxification of numerous environmental carcinogens. The genes coding for the isoforms glutathione-Stransferase-theta-1 (GSTT1) and -mu-1, (GSTM1) exhibit an inherited homozygous deletion polymorphism (null genotype), resulting in total lack of enzymatic activity. 2 The frequency of homozygous deletion genotypes of GSTT1 and GSTM1 varies by ethnicity, being 15-30% and 35-60% respectively, among Caucasians. 3 Several studies investigating the association and potential causative role of GSTs polymorphisms in MDS have come to conflicting conclusions, possibly due to the heterogeneity of these diseases, ethnic variations and/or methodological approaches. 4 To investigate the association and potential role of GST polymorphisms in MDS pathogenesis within a group of individuals with highly homogeneous ethnic background, we studied the GSTM1 and GSTT1 genotypes on a large cohort of Greek patients with primary MDS and healthy individuals. The study included 323 patients diagnosed with primary MDS between March 1999 and December 2004 (212 males, 111 females, range 19-92 years, median age 68 years). Diagnosis of MDS was established in the major Greek hospitals, according to the French American British classification criteria. Patients with MDS and history of previous cancer diagnosis or with history of chemo/radiotherapy were excluded from the study. Bone marrow samples at diagnosis were analyzed at the Cytogenetics Unit, NCSR 'Demokritos', for centralized karyotyping. From the same specimens, genomic DNA was extracted and used for subsequent genotypic analysis. Peripheral blood samples from 330 healthy donors were used as control samples. They were matched for sex and age (205 males, 125 females) (range: 20-89 years, median 65 years). These individuals were not related to the patients and had no past history of any malignancy. Informed consent was obtained from patients and controls at each participating center, in compliance with the recommendations of the Declaration of Helsinki. The study protocol was approved by the ethical committee of each center participating in the trial.
Cytogenetic analysis of bone marrow samples was performed using unstimulated short-term cultures. Karyotypes were described in accordance with the recommendations of the International System for Human Cytogenetic Nomenclature (ISCN 2005) . Patients were stratified according to the International Prognostic Scoring System (IPSS) cytogenetic classification into three risk groups, good: normal, del(5q) only, del(20q) only, ÀY only; intermediate: þ 8, single miscellaneous, double abnormalities and poor: complex (that is, X3 anomalies) or chromosome 7 abnormalities. 5 To verify 5q31 deletion, doublecolor fluorescent in situ hybridization studies were performed for EGR1 (5q31) and D5S23/D5S721 (5p15.2) (Vysis Inc., Downers Grove, IL, USA) in a total of 47 MDS cases with À5/del(5q).
To determine the presence or absence of GSTT1 and GSTM1 in genomic DNA, a differential polymerase chain reaction method reported by Chen et al. 6 was employed, using the housekeeping gene b-globin as internal control. Samples in which b-globin, but not GTSTT1 or/and GSTM1, polymerase chain reaction products were detected were considered null genotype and the findings were confirmed by repeating the procedure.
The statistical significance of differences between groups was calculated using w 2 -statistics with continuity correction or Fisher's exact test. A P-value less than 0.05 was considered statistically significant. Odds ratio was calculated and reported with 95% confidence intervals.
The clinical and cytogenetic features of our study group with primary MDS were found to be comparable to those of the IPSS database population (n ¼ 816), 5 a well-defined representative group of untreated primary MDS (data not shown). Genotypic analysis was successfully performed in 323 MDS cases for GSTT1 (212 males, 111 females) and in 302 for GSTM1 (200 males, 102 females). The frequencies of GSTT1-and GSTM1-null genotypes in patients and controls are summarized in Table 1 . Within the sample of healthy Greek donors, the observed frequencies of genotypes homozygous null for the GSTT1 and GSTM1 gene were 15.8 and 42.4%, respectively, which is in the range reported previously in other Caucasian populations (15-30% and 35-60%, respectively). 3 The incidence of the GSTT1-null genotype did not differ significantly between patients (58/323, 17.9%) and controls (52/330, 15.8%) (P ¼ 0.518). Similarly, no differences were obtained for the GSTM1-null genotype between controls (140/330, 42.4%) and patients (107/302, 35.4%) (P ¼ 0.086). Successful genotyping for both GSTT1 and GSTM1 was achieved in 294 cases. The combined null genotype frequency for both genes among patients (20/294, 6.8%) was not significantly different from that observed among control individuals (20/330, 6.06%) (P ¼ 0.830).
Our studies, which represent the largest series of patients with primary MDS ever evaluated for GSTT1 and GSTM1 gene polymorphisms, showed no significant differences in the frequencies of genotypes null for GSTT1, GSTM1 or the combined null genotype between MDS patients and control healthy individuals. Thus, GSTT1 and GSTM1 polymorphisms do not correlate with susceptibility to MDS. Our findings are in agreement with previous studies from Europe, Brazil and Japan reporting a comparable incidence of the GSTT1-null genotype in MDS patients and controls. On the contrary, studies with Japanese and American populations have reported a higher incidence of the GSTT1-null genotype in MDS patients than in controls. Our findings are also consistent with prior conclusions regarding the GSTM1 genotype in patients from Europe, USA, Brazil and Japan, reporting an equal distribution of null genotype between patients and controls.
We next compared the frequencies of GSTT1 and GSTM1 genotypes after grouping patients according to gender, age, French American British and IPSS classification. However, no significant differences in the frequencies of the null genotypes were observed among the various subgroups (Table 2) 6 The reasons for the conflicting reports regarding GST genotypes in MDS are unclear. They may be attributed to disease heterogeneity, distinct prevalence of clinical presentations in Eastern and Western patients, ethnic variations in GST genotypes affecting both patients and controls and geographic differences in the causes of MDS. Finally, the size of patient group, as well as the size and identity of the control group, are crucial factors affecting the outcome of case-control studies, because if inappropriate, they may lead to skewed results. 8 According to karyotype, the proportion of cytogenetically abnormal cases carrying the GSTT1-null genotype was 21.9%, and that for GSTM1-null was 37.5% (Table 2 ). These frequencies did not differ significantly from those among cases with a normal karyotype (17.4%, P ¼ 0.440 and 33.5%, P ¼ 0.604, respectively). Among cases with abnormal karyotype, the highest incidence of the GSTT1-null genotype was observed in the ÀY group (37.5%). However, this trend did not reach statistical significance. A trend for higher incidence of the GSTM1-null genotype was observed among our patients with À7/del(7q) (60%). Although its clinical significance is currently unclear, this is a noteworthy finding, since chromosome 7 aberrations in MDS are indicators of unfavorable prognosis associated with rapid leukemic evolution and/or poor response to chemotherapy.
When we analyzed GSTT1 and GSTM1 genotypes within the group of patients with sole 5q deletion, we observed that no GSTT1 gene deletion was detected in all five patients carrying a single chromosome 5q deletion (Table 2 ). An additional six patients who had À5/del(5q) as part of complex karyotype also showed a GSTT1-positive genotype (data not shown). A similar observation had previously been reported by Preudhomme et al. 7 (n ¼ 10). Admittedly, the number of cases in both studies is too small to draw safe conclusions. The absence of the GSTT1-null genotype in patients with isolated 5q deletion observed by two independent research groups in Greek and French patients with primary MDS, prompted us to further investigate the persistence of this association. To this end, we analyzed the GSTT1 gene status in 36 additional patients with primary MDS and À5/del(5q), recruited from a different series, thereby increasing the sample size to a total of 47 individuals. Using fluorescent in situ hybridization, we determined that 5q31/EGR1 deletion was present in all 47 cases. None among these 47 patients showed 5p15.2 (D5S23/D5S721) deletion, consistent with recent reports indicating that true monosomy 5 is rare in MDS/acute myeloid leukemia. 9 Among these 47 cases, 22 had an isolated 5q deletion, four showed 5q deletion accompanied by one additional abnormality and 21 had À5/ del(5q) as part of a complex karyotype (Table 3) . Strikingly, only two of these 47 patients (4.2%) exhibited a GSTT1-null genotype. Both these cases displayed 5q31 deletion as part of a complex karyotype (Table 3) . On the basis of these intriguing Abbreviations: GSTM1, glutathione-S-transferase-mu-1; GSTT1, glutathione-S-transferase-theta-1; MDS, myelodysplastic syndromes. a Genotype analysis was performed in 323 MDS cases for GSTT1.
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Genotype analysis was performed in 302 MDS cases for GSTM1. c A combined genotype was available for 294 patients.
Letters to the Editor findings, we sought to further investigate whether the low frequency of the GSTT1-null genotype was selectively associated with the presence of del(5q). For this purpose, we compared the frequencies of the GSTT1-null genotype among MDS patients with 5q31/EGR1 deletion and MDS patients with all types of karyotypic abnormalities. The frequency of the GSTT1-null genotype was significantly lower among patients with 5q31/EGR1 deletion as compared with that among MDS patients with all karyotypic abnormalities (4.2 vs 21.9%; odds ratio ¼ 6.3; 95% confidence interval ¼ 1.4-28; P ¼ 0.008). Moreover, the frequency of the GSTT1-null genotype among MDS patients with 5q31/EGR1 deletion was significantly lower than that among healthy control individuals (Table 3) .
These observations might suggest a potentially causative role of GSTT1 gene expression in the pathogenesis of this particular cytogenetic abnormality in primary MDS. It has been reported that a functional GSTT1 enzyme is required for some substances, such as organic solvents, to form mutagenic metabolites following conjugation with glutathione. 10 Interestingly, exposure to organic solvents has preferentially been associated with chromosome 5q abnormalities. 10 Thus, the presence of GSTT1 gene, while protective in general, may be considered as an 'at-risk' genotype for certain exposures promoting specific types of genetic damage. Because our only two patients with the GSTT1-null genotype in the 5q deletion group displayed 5q31 deletion as part of complex karyotypes, an intriguing hypothesis might be that the GSTT1-null genotype in del(5q) cases is associated with chromosomal instability, leading to an aggressive karyotype. These observations justify further studies to elucidate the biological significance of GSTT1 expression and its potentially causative role in the pathogenesis of certain cytogenetic abnormalities in primary MDS. Genotype analysis was performed in 302 MDS cases for GSTM1. Numbers (and percentages) of patients with null genotypes in each group are shown. P-values were estimated comparing the frequency distribution of each categorical variable (gender, age, FAB, IPSS, normal karyotype and karyotypic abnormality subgroups) among cases with presence and absence of GSTT1 or GSTM1 gene deletion. 
